doi: 10.3988/jcn.2021.17.1.11 [PubMed] 33664203 Rossetti AO, Alvarez V
Here are the key details: Start date: July 1, 2026 End date: December 31, 2027 (unless extended by Congress) Eligible medications: FDA-approved anti-obesity medications, including Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) Patient cost: Flat $50 per month copay Deductible: Waived - the Part D deductible does not apply to medications obtained through this program Prior authorization: Required by most Part D plans, but criteria are standardized under the program The bridge structure is important to understand
No insurance formulary includes it
Nasal delivery allows for more direct absorptionwithout needles, appointments, or downtimemaking it a practical option for women who want medical-grade support that fits into their daily lives
Across all experiments, semaglutide did not increase kaolin intake, suggesting that the behavioral changes observed were not caused by malaise
You M, Chen N, Yang Y, Cheng L, He H, Cai Y et al